K Moeremans

Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymphoma in Four European Countries

L Annemans, K Moeremans, Mark Lamotte et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2002 · 151 citations

Renal Pathology, Pathology, Tls Cases +17

Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients

Lieven Annemans, K Moeremans, Mark Lamotte et al. · Supportive Care in Cancer · 2003 · 77 citations

Tumour Lysis Syndrome, Urology, Oncology +7

Estimating the Cost-Effectiveness of Quality-Improving Interventions in Oral Anticoagulation Management within General Practice

Neree Claes, K Moeremans, Buntinx Frank et al. · Value in Health · 2006 · 38 citations · Full text

Thrombosis, Oral Anticoagulation Management, Preventive Medicine +12

Assessment of the economic value of the INTERCEPT blood system in Belgium

K Moeremans, Hans Warie, Lieven Annemans · Transfusion Medicine · 2006 · 28 citations

Long-term medical costs of postmenopausal breast cancer therapy

V. Cocquyt, K Moeremans, Lieven Annemans et al. · Annals of Oncology · 2003 · 25 citations · Full text

Breast Oncology, Health Economics, Medicine +7